BiotechTube
Home/Liquidia Corporation/David L. Johnson
DL

David L. Johnson

General Counsel & Corporate Secretary

Liquidia Corporation

Therapeutic Areas

Pulmonary Arterial HypertensionPulmonary Hypertension

Liquidia Corporation Pipeline

DrugIndicationPhase
YUTREPIA™ (treprostinil) inhalation powderPulmonary Arterial Hypertension (PAH)Approved
LIQ861 (treprostinil) inhalation powderPulmonary Arterial Hypertension (PAH)Phase 3
L606 (liposomal treprostinil) injectionPulmonary Arterial Hypertension (PAH)Preclinical

Leadership Team at Liquidia Corporation

RA
Roger A. Jeffs, Ph.D.
Chief Executive Officer & President
MK
Michael Kaseta
Chief Financial Officer & Treasurer
TS
Tushar Shah, M.D.
Chief Medical Officer
SB
Steven B. Simonson, M.D.
Senior Vice President, Clinical Development
JA
Jason Adair
Chief Operating Officer
SB
Stephen Bloch, M.D.
Chairman of the Board
View full Liquidia Corporation profile